SPRAVATO™ (esketamine) Spray
Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.
Individuals who have failed at least 2 antidepressant trials and meet criteria for severe major depressive disorder are eligible for esketamine treatment. Esketamine is not recommended for anyone with active substance use, individuals receiving benzodiazepines, individuals receiving MAOI antidepressants, and/or individuals taking stimulant medication.
Professional Referrals: If you are making a referral from outside the agency, please call our intake line at 844-224-5264 ext 104 send a fax to 888-509-0010 with evaluations, current/previous treatment plans, medications, recent physical exam, lab work, and immunization records. You may complete a professional referral by clicking this link.
Personal Referrals: If you are a self-referring patient, you may speak to an Intake Team member at 844-224-5264 ext 104 or fill out the registration form found here.
